2025 Adult Malignant Glioma Therapeutics Market Outlook: Key Indicators Shaping Growth Through 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Adult Malignant Glioma Therapeutics Industry Market Size Be by 2025?
The market for adult malignant glioma therapeutics has experienced swift expansion in the past few years. The market value, presently at $2.25 billion in 2024, is projected to rise to $2.48 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.4%. This development over the historic duration is due to a surge in incidence rates, initiatives advocating for patients, and the growth in personalized medical treatments.

What's the Long-Term Growth Forecast for the Adult Malignant Glioma Therapeutics Market Size Through 2029?
In the coming years, the adult malignant glioma therapeutics market is forecasted to witness significant expansion. The market is set to reach $3.55 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.4%. This predicted growth during the forecast period can be credited to advancements in immunotherapy and targeted therapies, the discovery of biomarkers, the application of liquid biopsies, and the introduction of expanded access programs. The forecast period is also expected to see major trends like the development of drugs with a focus on the patient, the fast-track and breakthrough designation, progress in drug delivery systems, collaborative research initiatives, and the introduction of artificial intelligence.

View the full report here:
https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

What Are the Key Growth Drivers Fueling the Adult Malignant Glioma Therapeutics Market Expansion?
The rising incidences of brain tumors are anticipated to fuel the adult malignant glioma therapeutics market expansion. A brain tumor is a non-standard mass of tissue where the typical biological regulations governing cells seem not to impede the unrestrained growth and cell multiplication. Adult malignant glioma is a variant of the brain tumor consisting of cells that multiply extraordinarily and unrestrainedly. The treatment of adult malignant glioma manages brain tumors using a combination of surgery, radiation therapy, and chemotherapy. For example, the American Cancer Society, a US nonprofit cancer advocacy organization, noted in January 2023 that brain and nervous system cancer cases had escalated to 24,810 in 2023, a boost of 3.85% from 23,890 in 2020. Thus, the escalating incidences of brain tumors are propelling the adult malignant glioma therapeutics market. An important catalyst for progress in Adult Malignant Glioma Therapeutics is governmental funding.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp

What Are the Key Trends Driving Adult Malignant Glioma Therapeutics Market Growth?
Leading firms in the adult malignant glioma therapeutics market are exploring new ways to improve customer service through the development of novel products such as small molecule targeted degraders. These are drugs that utilize small molecules to promote the degradation of specific proteins by focusing on the protein of interest (POI) and an E3 ubiquitin ligase. Beactica Therapeutics AB, a precision oncology company based in Sweden, for instance, obtained orphan drug designation approval from the U.S. Food and Drug Administration (FDA) in February 2023 for BEA-17, a treatment for glioblastoma (GBM). BEA-17 is a type of small molecule targeted degrader which acts on the epigenetic enzyme LSD1 and its co-factor CoREST, both known to be involved in the development of various cancers including GBM. By degrading LSD1 and CoREST, BEA-17 enables the reactivation of tumor suppressor genes and limits the growth of cancer cells.

How Is the Adult Malignant Glioma Therapeutics Market Segmented?
The adult malignant glioma therapeutics market covered in this report is segmented -

1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types
2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies
3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users

Subsegments:
1) By Glioblastoma Multiforme: Standard Treatments, Experimental Therapies
2) By Anaplastic Astrocytoma: Chemotherapy Options, Targeted Therapies
3) By Anaplastic Oligodendroglioma: Radiation Therapy, Combination Therapies
4) By Anaplastic Oligoastrocytoma: Surgical Interventions, Adjuvant Therapies
5) By Other Types: Rare Gliomas, Emerging Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13178&type=smp

Which Companies Are Leading the Charge in Adult Malignant Glioma Therapeutics Market Innovation?
Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan PLC, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

Which Regions Are Leading the Global Adult Malignant Glioma Therapeutics Market in Revenue?
North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13178

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.